导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -0.40% | 2301/4773 |
| 近一周 | -2.83% | 3225/5462 |
| 近一月 | -6.74% | 3611/5421 |
| 近一季 | 10.09% | 162/5209 |
| 近半年 | 0.47% | 1154/4920 |
| 近一年 | -13.60% | 3616/4366 |
| 近两年 | 26.70% | 2424/2954 |
| 近三年 | -7.14% | 2004/2253 |
| 成立以来 | 2.77% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.11% 2129/4961 |
-4.47% 3513/5312 |
- - |
- - |
| 2025 | 7.19% 2934/4813 |
1.54% 1602/3635 |
1.87% 2068/4076 |
19.69% 2111/4524 |
-13.42% 4303/4813 |
| 2024 | -12.35% 2372/3463 |
-11.36% 2428/2808 |
-9.56% 2374/3014 |
18.91% 909/3129 |
-8.05% 2825/3463 |
| 2023 | -10.22% 1277/2656 |
1.67% 1534/2280 |
-7.95% 1939/2385 |
-1.19% 489/2515 |
-2.91% 556/2655 |
| 2022 | -22.60% 1076/2207 |
-14.94% 1015/1919 |
2.30% 1318/2016 |
-17.75% 1638/2113 |
8.15% 272/2208 |
| 2021 | -6.05% 995/1822 |
-2.83% 715/1255 |
17.78% 180/1330 |
-16.76% 1403/1466 |
-1.38% 1361/1822 |
| 2020 | - - |
- - |
34.15% 24/1067 |
6.40% 842/1164 |
12.62% 449/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 富国中证医药50ETF VS. 长安沪深300非周期A(740101) |